Futura Medical
Futura Medical specialises in the development and global commercialisation of innovative consumer-focused sexual health products. Our lead projects are , Eroxon® (available commercially) and Eroxon® Intense and WSD4000 (both in-development). Our core strengths lie in our expertise in research and development, regulatory and business development in sexual health market.
Our vision is to be recognised as a global leader in the development of clinically proven, innovative, consumer-focused sexual health products..
Share Price
Eroxon®
Eroxon® is a breakthrough treatment for erectile dysfunction and is the only fast-acting topical clinically proven treatment for erectile dysfunction available without prescription in Europe and in the USA.
Eroxon® is clinically proven to help men achieve an erection within 10 minutes and is authorized by the FDA.
Eroxon® is available in 27 markets across the world including in the USA, Mexico, throughout most of Europe and a number of countries in the Middle East.
Our Products
Futura Medical specialises in the development and global commercialisation of innovative and proprietary consumer-focused sexual health products. Our lead project is Eroxon®, a clinically proven treatment for erectile dysfunction and we have two projects in our development pipeline Eroxon® Intense, a line extension for men who want a stronger and faster sensorial action and WSD4000, our in-development portfolio for female sexual health currently focused on a range of gels for the treatment of symptoms of impaired sexual response and function in
Business Model
Futura’s business model is based on a hybrid R&D and commercial strategy, providing flexibility to develop the most appropriate commercial structure by market. Futura has distribution or license partners in place for Eroxon® in a number of major consumer markets and we continue to seek new market opportunities with leading consumer healthcare companies to drive long-term sustainable growth.
Investor Centre
Our investor centre includes all key investor information such as corporate documents, share price chart and the information required pursuant to AIM Rule 26.
Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.
Our Commercial Model
Futura’s business model is based on an ‘actively manage and optimise’ approach focused on a hybrid R&D and commercial approach which will provide greater flexibility, insight development and sharing and improved economic participation across markets.